Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners

“We reviewed clinicopathological data of patients with ROS1-rearrangement who received crizotinib therapy at our institution between April 2014 and December 2016. ROS1 fusion partners were evaluated using Sanger sequencing for tumor tissue available.”

Read the entire article here

Published by


mom, wife, daughter, advocate, and stage IV lung cancer survivor.